INTRODUCTION
The Lesch-Nyhan syndrome is characterized by severe neurologic dysfunction resembling cerebral palsy (1) and an acceleration of de novo purine synthesis resistant to inhibition by purine analogs (2, 3) . In 1967 Seegmiller et al. (4) found this disorder was associated with almost complete absence of hypoxanthineguanine phosphoribosyltransferase (EC 2.4.2.8; HPRT)1 activity in red cells and fibroblasts from affected patients. The gene locus for HPRT is on the X-chromosome (5, 6) , and to date only affected boys have been described. In recent years it has become apparent that some Received for publication 6 November 1972 and in revised form 10 May 1973. 1 Abbreviations used in this paper: 8 deficiency associated with accelerated purinie synthesis and hvperuricemia (7, 8) . We have recently described a boy (C. A.) with a mild neurological deficit, hyperuricemia, and accelerated purine production resistant in vivo, (9) and in vitro to puriine analogs but with apparentlv normal HPRT activity in red cells and fibroblasts (10) . Studies of red cell HPRT from this patient revealed normal heat stability at 80°C and normal electrophoretic mobility at pH 8.6. However, several properties of C. M.'s fibroblasts in culture resembled those of cells from patients with the Lesch-Nyhan syndrome. In the present study we find that the red cell HPRT from this patient has abnormal kinetic properties w ith phosphoribosylpyrophosphate (PRPP) as substrate. These findings extend the range of nmutationis described at the HPRT locus in man, and have implications for purine analog-resistant leukemia where HPRT appears normal (11) .
METHODS
Forearm skin biopsy specimens were grown in Petri dishes and commercial F12 media (Gibco, Grand Island Biological Co., Grand Island, N. Y.) with supplemented 15% fetal calf serum. Cell strains were established from patients with the clinical symptoms described by Lesch and Nyhan (1) and almost complete HPRT deficiency (10) . Cell strain 23 was derived from a patient (C. M.) with hyperuricemia and apparently normal HPRT activity, whose history has been described in detail (10 Co., St. Louis, Mo., respectively. All other chemicals were of the highest quality available. HPRT activity was assayed at 37°C as previously described (13, 14) . Twice-washed red cells were frozen and thawed and dialyzed for 3 h against 0.005 M Tris pH 7.4 at 4°C. The final reaction mixture consisted of 50 mM Tris, 5 mM MgSO4, 1 mM PRPP, 0.6 mM hypoxanthine and enzyme at pH 7.7 in a final volume of 100 ul. -The reaction was stopped with 20 ul 4 M formic acid, and elution on descending paper chromatography with 5% NaH2PO4 was used to separate nucleotide product from labeled base (14) .
Red cell hemolysates were dialyzed for 3 h in 0.01 M sodium phosphate buffer, pH 6.05, and Pevikon block electrophoresis (15) was performed. The tray buffer consisted of 0.393 M sodium phosphate pH 6.2 (16) , and the gel buffer was diluted 1: 40 giving a pH of 6.05. Electrophoresis was run at 1 mA/cm for 4 h. 1-cm slices were cut out, the enzyme was eluted with 1 cm3 of 0.5 M Tris, pH 7.4, containing 0.01 M MgCl2, and the HPRT assay was carried out as described above. Hemoglobin was determined by converting it to cyanmethemoglobin and reading the optical density at 540 nm in a Beckman DU spectrophotometer (Beckman Instruments, Inc., Fullerton, Calif.). pH 7.4 dialyzed red cell hemolysates were added to prepared reaction mixtures to begin inhibition studies according to the general outline of Adye and Gots (17) . Kinetic studies were performed when HPRT enzyme activity was linear with time and proportional to enzyme concentration. Erythrocyte enzyme activity was measured with 2 X 10-' M hypoxanthine for PRPP kinetic studies. Hypoxanthine and guanine kinetic studies were carried out at 1 X 10' M PRPP for control HPRT and 3 x 10' M magnesium-PRPP for C. M. HPRT unless otherwise noted. Protein was estimated with bovine serum albumin as a standard (18) .
RESULTS
Tissue culture studies. C. M. fibroblasts and control fibroblasts differ from cells obtained from patients with the Lesch-Nyhan syndrome in their ability to grow in aminopterin and commercial F12 media containing thymidine and hypoxanthine (10) . Aminopterin inhibits the two tetrahydrofolate-requiring steps in de novo purine synthesis ( Fig. 1 ) and forces cells to obtain hypoxanthine from the media for growth. In Fig. 2 it may be seen that C. M. fibroblasts develop sensitivity to 8-azaguanine (8-AG) in the presence of aminopterin. C. M. cells in aminopterin demonstrate a threefold increase in purine transport (19) . A similar increase in 8-AG transport with conversion to its toxic ribonucleotide would explain growth inhibition of C. M. cells in aminopterin and 8-AG. It can be seen in Fig. 2 that cell strain 66, a kinetic HPRT mutant strain associated with the Lesch-Nyhan syndrome (12) , is resistant to 8-AG as has been described for cell strains from patients with classical Lesch-Nyhan syndrome (10).
Aza-L-serine, a second inhibitor of de novo purine synthesis, has a unique partial inhibitory effect on C. M. cell growth when compared to control fibroblasts (Fig.  3) . Lesch-Nyhan fibroblasts do not grow in the presence of this inhibitor. It could have been predicted that C. M. fibroblasts would demonstrate full growth in aza-L-serine as they do in aminopterin. We have not determined whether aza-L-serine affects other metabolic pathways in C. M. fibroblasts or if aza-L-serine inhibition of de novo purine synthesis is greater than that of aminopterin.
Red ceU HPRT. Previous starch gel studies have demonstrated that migration of C. M. HPRT is similar to control enzyme at pH 8.6 (10) . Studies at a second pH value were required to definitively establish this point. C. M. red cell HPRT migration was identical to (23) ( (8) - maximal velocity but altered kinetic properties and marked sensitivity to the sulfhydryl reagent p-chloromercuribenzoate (pCMB) compared to other enzyme inhibitors. Similar studies were carried out with enzyme from red cell hemolysates. Table I demonstrates that HPRT from C. M. hemolysates is sensitive to sodium fluoride. MAore recently, DeMars and Held (24) have extended these observations to cell strains vith induced HPRT mutations, and sodium fluoride sensitivity is again found.
HPRT kinetics. It caIn be seeni in Fig. 5 that hiiglh PRPP levels inhibits control HPRT activity. This was not described in the kinetic stu(lies of Hendersoin, Brox, Kelley, Rosenbloom, and Seegmiller (25) and Krenitsky et al. (14) but has been noted by Arnold and Kelley (22) . Difficulty was encountered in interpreting data like that shown in Fig. 5 . The first problem was that apparent PRPP Km values for C. Ml. HPRT, obtained from double reciprocal plots, were always higlher than expected by inspection of plots such as the insert, Fig. 5 . The second problem was that the apparent Km for PRPP with C. Al. HPRT was the same as the PRPP substrate level routinely used in the enzyme assay. One possible explanation was that total activity of C. MI. HPRT was not being determined when magnesium ion concentration was 5 mM. Magnesium ion concentrations were then raised, with PRPP levels constant at 1 mAM. C. AM. HPRT activity rose by 57% wc-hen magnesium ion levels were doubled to 10 mM. At 10-mM magnesium PRPP levels, C. M. HPRT activity rose from 75 to 138 /Amol hypoxanthine catalyzed/mg protein/h, significantly higher than the control activity of 80±+18 tmol/mg protein/h. Increased levels of HPRT activity in C. NI. red cell hemolysates may represent enzyme induction and are currently under investigation. These studies suggest that kinetic analysis of HPRT activity is more important than considerations of absolute levels of enzyme activity. on red cell enzyme obtained from patients with partial enzyme deficiency and gout (7). The original experiments in C. A. in vivo, demonstrating accelerated purine synthesis resistant to azathioprine, were interpreted to suggest that C. M. had a defect in the feedback regulation of purine synthesis (9) . This proved incorrect, for subsequent experiments in vitro demonstrated that C. MI. fibroblasts were more sensitive to feedback effects of adenine nucleotides than control cell strains, in a manner similar to cell strains grown from patients with the Lesch-Nyhan syndrome (10). We now find that C. Ml. has a distinct kinetic HPRT mutation, similar to but not as severe as that found in a patient with the LeschNyhan syndrome (12) . The enzymatic defect alters the enzyme affinity for PRPP (Fig. 5) , and not the apparent Michaelis constants of hypoxanthine or guanine. Similar kinetic defects in other enzymes have been demonstrated. Some pseudocholinesterase enzymes have apparently normiial maximal velocities but altered kinetic and inhibitory properties (27, 28 HypoxantNex 104) .HypoxontHne FIGURE 6 Lineweaver-Burke plots of dialyzed control and C. M. red cell hemolysate HPRT with hypoxanthine as the variable substrate and various levels of magnesium PRPP, soguanidine, and almost all mutants had considerably less than 1% of the HPRT activity of wild-type cells (33) . Initial results were similar in X-irradiated human fibroblasts (34), but more complete study reveals that 8-AGresistant low HPRT activity mutants resembling LeschNyhan cells are the minority of mutant cell lines isolated (24) ; at least 90% of them can utilize hypoxanthine for growth and have residual HPRT activities that range from low but significant levels to that found in one mutant cell strain, where HPRT activity could not be distinguished from control. It has been known for several years that purine analog resistance in human leukemia is associated with an apparently normal HPRT activity (11) . The spontaneous incidence of HPRT mutations in cultured human cells is about 5 X 10' (24) .
This makes selection for mutants in leukemic cell populations similar to C. M. cells probable, if in vitro conditions are an indicator of the in vivo mutation rate. Kinetic HPRT mutants similar to the one described here would explain the purine analogue resistance and apparently normal HPRT activity of cultured tumor cell lines (35) , hamster cells (36) , and human fibroblasts (24) .
Partial HPRT deficiency in man is currently thought to be a rare cause of accelerated purine synthesis and gout. In a recent series of 425 cases of hyperuricemia with gouty arthritis or uric acid stone formation, Yii et al. (32) found only seven subjects, including five in one family, with partial HPRT deficiency. Sperling et al. (37) have identified only one partial HPRT mutation out of 52 patients with primary gout and uric acid overproduction. However, two other brothers with gout in this series of patients had accelerated PRPP synthesis associated with accelerated uric acid production (38) . The mutation in this family may be X-linked, since the mother of these patients also has accelerated uric acid production (38) . A mutant HPRT would explain these findings. Kinetic or inhibition studies, or tests of purine analog resistance may identify more HPRT mutations in patients with gout or uric acid stone formation.
